Biotech Sector Soars On Valeant (VRX) Bid For Cephalon (CEPH)
Biopharmaceutical Stocks Ignited By M&A Potential M&A has been a key driver for investing in biotech stocks as need for product pipeline and technologies grows. The drug development process is slow and synergies can be found faster by buying companies on the open market. New drugs...
Rayno Life Science Portfolio: Cephalon (CEPH) Up 27% After Hours on Valeant (VRX) Hostile Bid- UPDATE
3/30/11 Update CEO Michael Pearson of Canadian based Valeant (VRX) reiterated his determination(live on CNBC this am) for buying Cephalon (CEPH) after being stalled by the Board of CEPH after initial discussions.Mr. Pearson stated he wanted to move quickly and if the deal stalls he would...
Rayno Life Science Portfolio Up 1.3% In A Strong NASDAQ Market
As has been the pattern lately biotech sector rallies coincide with NASDAQ with the NAZ (2753) up 20.2 or 0.81% . The mid caps are the sweet spot in the market with as our mid-cap index of 33 biotechs are almost all green with the average up 1.57%. 14 of the stocks are up 2% or more. The major...
Technology Convergence in Healthcare: Abbott (ABT), Alere (ALR) and Merge (MRGE)
In January we reported from the JPMorgan Healthcare Conference regarding convergence of communications and medical technologies. Two trends mentioned were use of cloud computing and connectivity in medicine. Here is a brief update: Abbott (ABT $48) announced today that the FDA cleared its...
Ariad (ARIA) and MolecularMD Collaborate in Companion Dx for CML
Ariad (ARIA $7.24 up 4.3%) continues to roll on today on heavy volume up 17% over 5 days on speculation, news and upgrades with strong expectations for their chronic myeloid leukemia drug ponatinib. Articles from Motley Fool, Seeking Alpha and The Street.com have spotlighted the Company and...